ASPIC

Harnack House, conference centre of the Max Planck Society, Berlin, Germany

27 - 29 November 2017

See more informations here: https://www.eacr.org/conference/seedandsoil2017

Harnack House, conference centre of the Max Planck Society, Berlin, Germany

27 - 29 November 2017

See more informations here: https://www.eacr.org/conference/seedandsoil2017

Cetuximab is the only anti-EGFR treatment approved for the treatment of head and neck tumors, however, an insufficient response rates have been reported in HNSCC patients. For this reason, in last years, a new class of anti-EGFR (afatinib and allitinib) with covalent and irreversible action to others members of EGFR family were designed.  In our study, we demonstrated the higher efficiency of these irreversible inhibitors when compared to cetuximab. In addition, we found a persistent AKT phosphorylation in resistant cell lines treated with anti-EGFR inhibitors.

O cetuximab é único tratamento anti-EGFR aprovado para o tratamento dos tumores de cabeça e pescoço, porém têm apresentado insuficientes taxas de respostas devido aos mecanismos de resistência. Diante disso, novas abordagem terapêuticas emergiram neste cenário, sendo representada pelos inibidores de EGFR, afatinib e allitinib, que possuem uma ligação covalente e irreversível ao EGFR e outros membros desta família. Em nosso estudo demonstramos a maior eficiência destes inibidores irreversíveis, comparados ao cetuximab.

Two young doctors from the Portuguese Institute of Oncology of Lisbon reviewed the clinical files of more than 2,000 patients with Differentiated Thyroid Cancer and evaluated the risk of developing other primary cancer elsewhere. They concluded that total administered activities of Iodine-131 above 200mCi could increase the risk. But the administration of low activities was not associated with the risk of having other cancers. The Differentiated Thyroid Cancer is the most common cancer in endocrinology and it is believed its incidence will increase in the next years.

Duas médicas do IPOLFG reviram o processo clínico de mais de 2.000 de doentes com cancro diferenciado da tiróide e avaliaram o risco de desenvolverem outras neoplasias primárias. Verificaram que actividades acumuladas de Iodo-131 acima dos 200mCi podem ter influência. A administração de actividades mais baixas, parece não ter riscos associados. Este cancro é o mais frequente em endocrinologia e prevê-se que a sua incidência aumente significativamente.

Authors and Affiliations:

Estela Maria Silva^1#, Vânia Sammartino Mariano^1#, Paula Roberta Aguiar Pastrez¹, Miguel Cordoba Pinto², António Gil Castro^3,4, Kari Juhani Syrjanen⁵, Adhemar LongattoFilho1,3,4,6

¹ Teaching and Research Institute, Barretos Cancer Hospital–Pio XII Foundation, Barretos, Sao Paulo, Brazil,

² Department of Chest, Barretos Cancer Hospital–Pio XII Foundation, Barretos, Sao Paulo, Brazil,

Autores e Afiliações:

Estela Maria Silva^1#, Vânia Sammartino Mariano^1#, Paula Roberta Aguiar Pastrez¹, Miguel Cordoba Pinto², António Gil Castro^3,4, Kari Juhani Syrjanen⁵, Adhemar LongattoFilho1,3,4,6

¹ Teaching and Research Institute, Barretos Cancer Hospital–Pio XII Foundation, Barretos, Sao Paulo, Brazil,

² Department of Chest, Barretos Cancer Hospital–Pio XII Foundation, Barretos, Sao Paulo, Brazil,